✦ LIBER ✦

In silico repositioning of approved drugs for rare and neglected diseases

✍ Scribed by Sean Ekins; Antony J. Williams; Matthew D. Krasowski; Joel S. Freundlich

Book ID: 113569320
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 686 KB
Volume: 16
Category: Article
ISSN: 1359-6446
DOI: 10.1016/j.drudis.2011.02.016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Role of Academic Institutions in the

The Role of Academic Institutions in the Development of Drugs for Rare and Neglected Diseases

✍ Coles, L D; Cloyd, J C 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 417 KB

Pivotal studies of orphan drugs approved

Pivotal studies of orphan drugs approved for neurological diseases

✍ Jun Mitsumoto; E. Ray Dorsey; Christopher A. Beck; Karl Kieburtz; Robert C. Grig 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

[RSC Drug Discovery] Neglected Diseases

[RSC Drug Discovery] Neglected Diseases and Drug Discovery || Chapter 4. Human Targets Repositioning and Cell-based Approaches for Antimalarial Discovery

✍ Palmer, Mike; Wells, Timothy N.C. 📂 Article 📅 2011 🏛 Royal Society of Chemistry ⚖ 592 KB

Clinical data packages of drug approval

Clinical data packages of drug approval for neurological diseases in Japan

✍ Sakushima, K.; Nakamura, H.; Hashizume, A. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 56 KB

PHP28 Drugs for Rare Diseases: Influence

PHP28 Drugs for Rare Diseases: Influence of Oprhan Designation Status on Price

✍ E. Picavet; M. Dooms; D. Cassiman; S. Simoens 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Biologics for Inflammatory Bowel Disease

Biologics for Inflammatory Bowel Disease: Drug Approval and Monitoring in the United States

✍ Tremaine, William J. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 118 KB